Insider Transactions in Q4 2021 at Intra Cellular Therapies, Inc. (ITCI)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
300
+0.39%
|
$15,600
$52.34 P/Share
|
|
Dec 31
2021
|
Robert L Van Nostrand |
BUY
Grant, award, or other acquisition
|
Direct |
148
+1.65%
|
$7,696
$52.34 P/Share
|
|
Dec 21
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
SELL
Open market or private sale
|
Direct |
175,000
-68.01%
|
$8,050,000
$46.41 P/Share
|
|
Dec 21
2021
|
Lawrence J. Hineline SVP of Finance, CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
175,000
+36.78%
|
$2,800,000
$16.72 P/Share
|
|
Dec 21
2021
|
Michael Halstead EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
176,863
-64.21%
|
$8,135,698
$46.79 P/Share
|
|
Dec 21
2021
|
Michael Halstead EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
176,863
+40.09%
|
$2,652,945
$15.72 P/Share
|
|
Oct 18
2021
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
13,448
-6.21%
|
$537,920
$40.15 P/Share
|
|
Oct 18
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
8,192
-0.74%
|
$327,680
$40.0 P/Share
|
|
Oct 15
2021
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,448
+18.62%
|
-
|
|
Oct 15
2021
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,075
+0.1%
|
$2,150
$2.84 P/Share
|
|
Oct 15
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,392
-3.54%
|
$1,615,680
$40.0 P/Share
|
|
Oct 14
2021
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
1,416
-0.12%
|
$56,640
$40.0 P/Share
|